Jefferies has increased its price target for Kiniksa (KNSA, Financial) from $40 to $45, while maintaining a Buy rating on the stock. This decision follows an impressive first-quarter performance, which the firm describes as a "beat and raise" scenario. The analyst attributes this positive outlook to the company's effective commercial strategies and anticipates continued robust growth in revenue from Arcalyst.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Kiniksa Pharmaceuticals International PLC (KNSA, Financial) is $35.57 with a high estimate of $40.00 and a low estimate of $30.00. The average target implies an upside of 37.18% from the current price of $25.93. More detailed estimate data can be found on the Kiniksa Pharmaceuticals International PLC (KNSA) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Kiniksa Pharmaceuticals International PLC's (KNSA, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Kiniksa Pharmaceuticals International PLC (KNSA, Financial) in one year is $44.90, suggesting a upside of 73.16% from the current price of $25.93. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Kiniksa Pharmaceuticals International PLC (KNSA) Summary page.
